This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Takaoka, S. Articles by Doyle, R. Search for Related Content PubMed PubMed Citation Articles by Takaoka, S. Articles by Doyle, R. Social Bookmarking                   What's this?

Current Therapies for Pulmonary Arterial Hypertension

Division of Pulmonary/Critical Care Medicine, Stanford University Medical Center, Stanford, California

John L. Faul, MD

Division of Pulmonary/Critical Care Medicine, Stanford University Medical Center, Stanford, California, Vera M. Wall Center for Pulmonary Vascular Disease, Stanford University Medical Center, Stanford, California

Ramona Doyle, MD

Division of Pulmonary/Critical Care Medicine, Stanford University Medical Center, Stanford, California, rldoyle{at}stanford.edu, Vera M. Wall Center for Pulmonary Vascular Disease, Stanford University Medical Center, Stanford, California

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature, characterized by relentless deterioration and death. Patients with PAH are known to be at increased risk for anesthetic complications and surgical morbidity and mortality. However, outcomes in patients have improved with the recent development of new drug therapies. The 3 major drug classes for treatment of PAH are prostanoids, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors. In this review, the authors provide an overview of each drug class, its mechanism of action, indications, and current supportive literature. Surgical and interventional treatments of PAH, including atrial septostomy, pulmonary thromboendarterectomy, and transplantation, are briefly reviewed, and the rationale, indications, and selection criteria for each are discussed. Although available medical and surgical therapies for PAH have improved patient outcomes, acute decompensated right heart failure (RHF) remains a common and challenging complication of PAH. The authors review this topic and provide an outline of the general pathophysiology of RHF and an approach to its management.

Key Words: pulmonary arterial hypertension • medical treatments • interventions

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?